Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients

A. M. Myint, M. J. Schwarz, R. Verkerk, H. H. Mueller, J. Zach, S. Scharpé, H. W.M. Steinbusch, B. E. Leonard, Yong Ku Kim

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The association between the pro-inflammatory state of schizophrenia and increased tryptophan degradation into kynurenine has been reported. However, the relationship between metabolites from subdivisions of the kynurenine pathway, kynurenic acid and 3-hydroxykynurenine, remains unknown. The present study tested the relationship between these kynurenine metabolites in the plasma of medication-naïve (n= 35) or medication-free (n= 18) patients with schizophrenia at admission and following 6-week antipsychotic treatment compared to healthy controls (n= 48). The plasma concentrations of kynurenic acid (nmol/l) were lower (difference = -8.44 (-13.22 to -3.65); p= 0.001) and of 3-hydroxykynurenine (nmol/l) were higher (difference = 11.24 (8.11-14.37); p< 0.001) in the patients compared with the healthy controls. The kynurenic acid/kynurenine (difference = -2.75 (-5.115 to -0.336); p= 0.026) and kynurenic acid/3-hydroxykynurenine (difference = -1.08 (-1.431 to -0.729); p< 0.001) ratios were also lower in the patients. After the 6-week treatment, the patients' plasma kynurenic acid levels (difference = 3.85 (-0.23 to 7.94); p= 0.064) showed a trend towards an increase, whereas plasma 3-hydroxykynurenine levels (difference = 22.41 (19.76-25.07); p< 0.001) decreased. As a consequence, the kynurenic acid/3-hydroxykynurenine ratio (difference = -4.41 (-5.51 to -3.3); p< 0.001) increased. Higher initial plasma kynurenic acid levels on admission or increased kynurenic acid/kynurenine ratio after treatment were associated with reduction of clinical symptoms scores upon discharge although higher kynurenic acid/kynurenine on admission may induce higher positive symptoms score. In contrast, higher 3-hydroxykynurenine is associated with lower positive symptoms score. These results indicate that there is an imbalance in the kynurenine pathway in schizophrenia. The 6-week antipsychotic treatment may partially reverse the imbalance in kynurenine metabolism and that in turn induces clinical response.

Original languageEnglish
Pages (from-to)1576-1581
Number of pages6
JournalBrain, Behavior, and Immunity
Volume25
Issue number8
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Kynurenic Acid
Kynurenine
Antipsychotic Agents
Schizophrenia
3-hydroxykynurenine
Therapeutics
Tryptophan

Keywords

  • 3-Hydroxykynurenine
  • Antipsychotics
  • Kynurenic acid
  • Kynurenine
  • Schizophrenia

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. / Myint, A. M.; Schwarz, M. J.; Verkerk, R.; Mueller, H. H.; Zach, J.; Scharpé, S.; Steinbusch, H. W.M.; Leonard, B. E.; Kim, Yong Ku.

In: Brain, Behavior, and Immunity, Vol. 25, No. 8, 01.11.2011, p. 1576-1581.

Research output: Contribution to journalArticle

Myint, A. M. ; Schwarz, M. J. ; Verkerk, R. ; Mueller, H. H. ; Zach, J. ; Scharpé, S. ; Steinbusch, H. W.M. ; Leonard, B. E. ; Kim, Yong Ku. / Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. In: Brain, Behavior, and Immunity. 2011 ; Vol. 25, No. 8. pp. 1576-1581.
@article{05b437535c324dd5ad6d7dedc0796856,
title = "Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-na{\"i}ve and medication-free schizophrenic patients",
abstract = "The association between the pro-inflammatory state of schizophrenia and increased tryptophan degradation into kynurenine has been reported. However, the relationship between metabolites from subdivisions of the kynurenine pathway, kynurenic acid and 3-hydroxykynurenine, remains unknown. The present study tested the relationship between these kynurenine metabolites in the plasma of medication-na{\"i}ve (n= 35) or medication-free (n= 18) patients with schizophrenia at admission and following 6-week antipsychotic treatment compared to healthy controls (n= 48). The plasma concentrations of kynurenic acid (nmol/l) were lower (difference = -8.44 (-13.22 to -3.65); p= 0.001) and of 3-hydroxykynurenine (nmol/l) were higher (difference = 11.24 (8.11-14.37); p< 0.001) in the patients compared with the healthy controls. The kynurenic acid/kynurenine (difference = -2.75 (-5.115 to -0.336); p= 0.026) and kynurenic acid/3-hydroxykynurenine (difference = -1.08 (-1.431 to -0.729); p< 0.001) ratios were also lower in the patients. After the 6-week treatment, the patients' plasma kynurenic acid levels (difference = 3.85 (-0.23 to 7.94); p= 0.064) showed a trend towards an increase, whereas plasma 3-hydroxykynurenine levels (difference = 22.41 (19.76-25.07); p< 0.001) decreased. As a consequence, the kynurenic acid/3-hydroxykynurenine ratio (difference = -4.41 (-5.51 to -3.3); p< 0.001) increased. Higher initial plasma kynurenic acid levels on admission or increased kynurenic acid/kynurenine ratio after treatment were associated with reduction of clinical symptoms scores upon discharge although higher kynurenic acid/kynurenine on admission may induce higher positive symptoms score. In contrast, higher 3-hydroxykynurenine is associated with lower positive symptoms score. These results indicate that there is an imbalance in the kynurenine pathway in schizophrenia. The 6-week antipsychotic treatment may partially reverse the imbalance in kynurenine metabolism and that in turn induces clinical response.",
keywords = "3-Hydroxykynurenine, Antipsychotics, Kynurenic acid, Kynurenine, Schizophrenia",
author = "Myint, {A. M.} and Schwarz, {M. J.} and R. Verkerk and Mueller, {H. H.} and J. Zach and S. Scharp{\'e} and Steinbusch, {H. W.M.} and Leonard, {B. E.} and Kim, {Yong Ku}",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.bbi.2011.05.005",
language = "English",
volume = "25",
pages = "1576--1581",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",
number = "8",

}

TY - JOUR

T1 - Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients

AU - Myint, A. M.

AU - Schwarz, M. J.

AU - Verkerk, R.

AU - Mueller, H. H.

AU - Zach, J.

AU - Scharpé, S.

AU - Steinbusch, H. W.M.

AU - Leonard, B. E.

AU - Kim, Yong Ku

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The association between the pro-inflammatory state of schizophrenia and increased tryptophan degradation into kynurenine has been reported. However, the relationship between metabolites from subdivisions of the kynurenine pathway, kynurenic acid and 3-hydroxykynurenine, remains unknown. The present study tested the relationship between these kynurenine metabolites in the plasma of medication-naïve (n= 35) or medication-free (n= 18) patients with schizophrenia at admission and following 6-week antipsychotic treatment compared to healthy controls (n= 48). The plasma concentrations of kynurenic acid (nmol/l) were lower (difference = -8.44 (-13.22 to -3.65); p= 0.001) and of 3-hydroxykynurenine (nmol/l) were higher (difference = 11.24 (8.11-14.37); p< 0.001) in the patients compared with the healthy controls. The kynurenic acid/kynurenine (difference = -2.75 (-5.115 to -0.336); p= 0.026) and kynurenic acid/3-hydroxykynurenine (difference = -1.08 (-1.431 to -0.729); p< 0.001) ratios were also lower in the patients. After the 6-week treatment, the patients' plasma kynurenic acid levels (difference = 3.85 (-0.23 to 7.94); p= 0.064) showed a trend towards an increase, whereas plasma 3-hydroxykynurenine levels (difference = 22.41 (19.76-25.07); p< 0.001) decreased. As a consequence, the kynurenic acid/3-hydroxykynurenine ratio (difference = -4.41 (-5.51 to -3.3); p< 0.001) increased. Higher initial plasma kynurenic acid levels on admission or increased kynurenic acid/kynurenine ratio after treatment were associated with reduction of clinical symptoms scores upon discharge although higher kynurenic acid/kynurenine on admission may induce higher positive symptoms score. In contrast, higher 3-hydroxykynurenine is associated with lower positive symptoms score. These results indicate that there is an imbalance in the kynurenine pathway in schizophrenia. The 6-week antipsychotic treatment may partially reverse the imbalance in kynurenine metabolism and that in turn induces clinical response.

AB - The association between the pro-inflammatory state of schizophrenia and increased tryptophan degradation into kynurenine has been reported. However, the relationship between metabolites from subdivisions of the kynurenine pathway, kynurenic acid and 3-hydroxykynurenine, remains unknown. The present study tested the relationship between these kynurenine metabolites in the plasma of medication-naïve (n= 35) or medication-free (n= 18) patients with schizophrenia at admission and following 6-week antipsychotic treatment compared to healthy controls (n= 48). The plasma concentrations of kynurenic acid (nmol/l) were lower (difference = -8.44 (-13.22 to -3.65); p= 0.001) and of 3-hydroxykynurenine (nmol/l) were higher (difference = 11.24 (8.11-14.37); p< 0.001) in the patients compared with the healthy controls. The kynurenic acid/kynurenine (difference = -2.75 (-5.115 to -0.336); p= 0.026) and kynurenic acid/3-hydroxykynurenine (difference = -1.08 (-1.431 to -0.729); p< 0.001) ratios were also lower in the patients. After the 6-week treatment, the patients' plasma kynurenic acid levels (difference = 3.85 (-0.23 to 7.94); p= 0.064) showed a trend towards an increase, whereas plasma 3-hydroxykynurenine levels (difference = 22.41 (19.76-25.07); p< 0.001) decreased. As a consequence, the kynurenic acid/3-hydroxykynurenine ratio (difference = -4.41 (-5.51 to -3.3); p< 0.001) increased. Higher initial plasma kynurenic acid levels on admission or increased kynurenic acid/kynurenine ratio after treatment were associated with reduction of clinical symptoms scores upon discharge although higher kynurenic acid/kynurenine on admission may induce higher positive symptoms score. In contrast, higher 3-hydroxykynurenine is associated with lower positive symptoms score. These results indicate that there is an imbalance in the kynurenine pathway in schizophrenia. The 6-week antipsychotic treatment may partially reverse the imbalance in kynurenine metabolism and that in turn induces clinical response.

KW - 3-Hydroxykynurenine

KW - Antipsychotics

KW - Kynurenic acid

KW - Kynurenine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=80053900888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053900888&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2011.05.005

DO - 10.1016/j.bbi.2011.05.005

M3 - Article

VL - 25

SP - 1576

EP - 1581

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

IS - 8

ER -